bausch health companies inc glp-1 receptor agonist medications GLP-1 Agonists: A Comprehensive Overview
Description
Back Molteni, M (17 Oct 2023) 'How one scientist's determination made Novo Nordisk an obesity-drug powerhouse', STAT News
Also, the inclusion of the drugs in public drug formularies and expanded insurance coverage for chronic condition management escalates accessibility, especially for underserved populations, and is driving the demand and growth of the market
[DOI] [PubMed] [Google Scholar] 163.Ellingsgaard H., Ehses J.A., Hammar E.B., Van Lommel L., Quintens R., Martens G
doi: 10.1139/y03-107
